Cytokinetics’ M&A roller-coaster

A wild week during the J.P. Morgan Healthcare Conference saw top M&A target Cytokinetics make it to Friday without a deal being announced — at least not yet.

Amid a flurry of M&A transactions over the past two months, Cytokinetics Inc. (NASDAQ:CYTK) may be the largest deal yet that hasn’t come to fruition. The rumors first surfaced on Dec. 21, just six days before the biotech announced positive top-line data from the Phase III SEQUOIA-HCM trial that investors interpreted as potentially putting aficamten in position as the best-in-class therapy to treat obstructive hypertrophic cardiomyopathy. ...